Thromboembolic disorders
Conditions
Interventions
None listed
Sponsors
CRISPR Therapeutics AG
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Outcome results
None listed
A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Ranging Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTX611 in Healthy Adult Participants
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Jul 11, 2026